Russell Investments Group Ltd. reduced its position in Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 14.9% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 23,159 shares of the biopharmaceutical company’s stock after selling 4,054 shares during the period. Russell Investments Group Ltd. owned 0.10% of Esperion Therapeutics worth $1,072,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Meditor Group Ltd acquired a new stake in shares of Esperion Therapeutics in the 2nd quarter valued at $26,194,000. US Bancorp DE grew its stake in shares of Esperion Therapeutics by 1.1% during the second quarter. US Bancorp DE now owns 9,856 shares of the biopharmaceutical company’s stock worth $457,000 after purchasing an additional 104 shares during the period. Peregrine Capital Management LLC acquired a new stake in shares of Esperion Therapeutics during the second quarter worth $14,748,000. Aperio Group LLC acquired a new stake in shares of Esperion Therapeutics during the second quarter worth $249,000. Finally, Credit Suisse AG grew its stake in shares of Esperion Therapeutics by 26.4% during the first quarter. Credit Suisse AG now owns 878,824 shares of the biopharmaceutical company’s stock worth $31,030,000 after purchasing an additional 183,440 shares during the period. 83.30% of the stock is owned by institutional investors.
Several research analysts have weighed in on ESPR shares. ValuEngine upgraded Esperion Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Deutsche Bank AG assumed coverage on Esperion Therapeutics in a report on Friday, June 23rd. They set a “buy” rating and a $48.00 target price on the stock. BidaskClub lowered Esperion Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, August 4th. Cowen and Company assumed coverage on Esperion Therapeutics in a report on Thursday, September 7th. They issued an “outperform” rating and a $64.00 price target on the stock. Finally, Citigroup Inc. restated a “buy” rating on shares of Esperion Therapeutics in a report on Thursday, June 22nd. Seven research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Esperion Therapeutics currently has an average rating of “Buy” and an average price target of $52.54.
COPYRIGHT VIOLATION WARNING: This piece was reported by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this piece can be read at https://stocknewstimes.com/2017/09/20/esperion-therapeutics-inc-espr-shares-sold-by-russell-investments-group-ltd.html.
Esperion Therapeutics, Inc. (NASDAQ:ESPR) traded up 0.34% during trading on Wednesday, hitting $49.74. The stock had a trading volume of 187,992 shares. The firm has a 50 day moving average price of $48.34 and a 200-day moving average price of $40.88. Esperion Therapeutics, Inc. has a 1-year low of $9.40 and a 1-year high of $57.38. The firm’s market capitalization is $1.12 billion.
Esperion Therapeutics (NASDAQ:ESPR) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.92) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.67) by ($0.25). During the same quarter in the prior year, the firm earned ($0.62) EPS. On average, equities research analysts expect that Esperion Therapeutics, Inc. will post ($7.29) EPS for the current year.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.